Spotlight on Allergy & Immunology
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
StartActivity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Allergy & Immunology Presentations
Improving Adult Vaccine Confidence: A GameOn! Challenge
StartActivity Details
/ABIM MOC
Expires: August 5, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
- Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
- Use effective strategies to educate adult patients and increase their vaccine confidence.
Activity Description
Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.
Faculty
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
- Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
- Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: August 5, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
- Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
- Use effective strategies to educate adult patients and increase their vaccine confidence.
Activity Description
Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.
Faculty
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA
Disclosure: No relevant financial relationships to disclose.
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
- Disclosure: No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
- Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
- Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.5 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence
StartActivity Details
Expires: July 22, 2021
Accredited By
Target Audience
This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.
Learning Objectives
- Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
- Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
- Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
- Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations
Activity Description
Interactive Puzzle Activity
Statement of Educational Need
Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma.
Faculty
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Reynold A. Panettieri, Jr., MD
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Activity Details
Expires: July 22, 2021
Accredited By
Target Audience
This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.
Learning Objectives
- Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
- Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
- Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
- Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations
Activity Description
Interactive Puzzle Activity
Statement of Educational Need
Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma.
Faculty
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Reynold A. Panettieri, Jr., MD
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions About the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
StartActivity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
- Disclosure:
- Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
- Speakers Bureau: Sanofi Pasteur
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: An Adult Patient With Asthma and Symptoms of
Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient
StartActivity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
- Disclosure:
- Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
- Speakers Bureau: Merck, Oxford Immunotec, Xenex
- Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
- Ownership Interest: Xenex
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: Managing Flu in an Immunocompromised
Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA,
FACP
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
/ABIM MOC
Expires: June 28, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
- Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.
Activity Description
In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
- Disclosure:
- Consulting Fee: Advanced Biotherapeutics, DiaSorin
- Ownership Interest: Johnson & Johnson
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
- Disclosure:
- Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
- Speakers Bureau: Merck, Oxford Immunotec, Xenex
- Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
- Ownership Interest: Xenex
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to
disclose.
Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to
disclose.
Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Agenda
Curbside Consult: Managing Flu in an Immunocompromised
Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA,
FACP
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this
CME activity enables the participant to earn up to 0.25 MOC points in the
American Board of Internal Medicine’s (ABIM) Maintenance of Certification
(MOC) program. Participants who opt-in will earn MOC points equivalent to the
amount of CME credits claimed for the activity. It is the CME activity
provider’s responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC points.
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.
Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ
CME Questions?
Contact us at CME@VindicoCME.com
Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions
StartActivity Details
1.0 Contact Hour(s)
Expires: June 25, 2021
Accredited By
This CME activity for ACCME credit is provided by Integrity Continuing
Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global
Education Group and Integrity Continuing Education.
Target Audience
This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the role of eosinophilia in severe asthma and EGPA
- Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
- Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids
Activity Description
This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.
Statement of Educational Need
In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.
Faculty
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia
Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.
Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.
Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.
Designation of Credit
Physician Credit
Integrity
Continuing Education is accredited with commendation by the Accreditation
Council for Continuing Medical Education to provide continuing medical
education for physicians.
Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of
nursing continuing professional development by the American Nurses
Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global
Education Group is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for
1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for
Pharmacy Education. (Universal Activity Number
This is a knowledge-based activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions about the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.
For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
1.0 Contact Hour(s)
Expires: June 25, 2021
Accredited By
This CME activity for ACCME credit is provided by Integrity Continuing
Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global
Education Group and Integrity Continuing Education.
Target Audience
This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the role of eosinophilia in severe asthma and EGPA
- Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
- Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids
Activity Description
This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.
Statement of Educational Need
In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.
Faculty
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia
Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.
Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.
Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.
Designation of Credit
Physician Credit
Integrity
Continuing Education is accredited with commendation by the Accreditation
Council for Continuing Medical Education to provide continuing medical
education for physicians.
Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of
nursing continuing professional development by the American Nurses
Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Global
Education Group is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for
1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for
Pharmacy Education. (Universal Activity Number
This is a knowledge-based activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.
Statement of Commercial Support
This activity is supported by an educational grant from GlaxoSmithKline LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions about the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.
For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Lupus
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. John Tesser will discuss the diagnosis and treatment of systemic lupus erythematosus.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.5 MOC
points in the American Board of Internal Medicine’s (ABIM) Maintenance
of Certification (MOC) program. Participants who opt-in will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com